Portal hypertension in metabolic dysfunction-associated steatotic liver disease: mechanisms of endothelial dysfunction, sinusoidal remodeling, and emerging therapeutic targets (review)

Background. Metabolic dysfunction-associated steatotic liver disease is one of the most prevalent chronic liver disorders worldwide and a systemic metabolic condition associated with cardiovascular, renal, and endocrine complications. Portal hypertension has traditionally been regarded as a consequence of advanced cirrhosis; however, accumulating evidence indicates that increased intrahepatic vascular resistance may develop at early stages of this disease, prior to the establishment of advanced fibrosis, warranting a comprehensive synthesis of the underlying mechanisms. The purpose of the article was to summarize and analyze current scientific evidence regarding the mechanisms underlying the development of portal hypertension in metabolic dysfunction-associated steatotic liver disease, with particular emphasis on metabolic dysregulation, endothelial dysfunction, intrahepatic microcirculatory disturbances, and fibrogenesis, and to evaluate modern diagnostic approaches and emerging therapeutic strategies targeting endothelial function and intrahepatic hemodynamics. Materials and methods. A narrative literature review was conducted using the PubMed, Scopus, Web of Science, Cochrane Library, and Google Scholar databases, covering the period from 2005 to 2025 and including systematic reviews, meta-analyses, randomized controlled and experimental studies, and clinical practice guidelines. Results. Dysfunction of liver sinusoidal endothelial cells, manifested by loss of fenestrations and sinusoidal capillarization, together with imbalance of vasoactive mediators — reduced nitric oxide bioavailability and increased endothelin-1 activity — and activation of hepatic stellate cells, constitutes a functional component of intrahepatic vascular resistance that may precede advanced fibrosis. Clinically significant portal hypertension, defined as a hepatic venous pressure gradient of 10 mmHg or more, is present in 61.5 % of patients with compensated advanced chronic liver disease related to metabolic dysfunction-associated steatotic liver disease, while the hemodynamic profile of nonalcoholic steatohepatitis differs from that of viral- or alcohol-related liver disease, particularly among patients with obesity. Conclusions. Portal hypertension in metabolic dysfunction-associated steatotic liver disease results from the interaction of functional (vascular tone) and structural (fibrosis) components of vascular resistance, accounting for the variability in clinical course. Understanding these mechanisms provides a basis for developing noninvasive diagnostic criteria and targeted therapeutic strategies aimed at restoring endothelial function at early, potentially reversible stages of the disease.

Authors

Institutions

Publication Details

Journal
INTERNATIONAL JOURNAL OF ENDOCRINOLOGY (Ukraine)
Published
2026-11-14
DOI
https://doi.org/10.22141/2224-0721.22.7.2026.1788
Primary Topic
Liver Disease Diagnosis and Treatment
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Portal hypertension in metabolic dysfunction-associated steatotic liver disease: mechanisms of endothelial dysfunction, sinusoidal remodeling, and emerging therapeutic targets (review)

Liudmyla Mikulets, Ю. М. Яринич, А. А. Антонів, Людмила Володимирівна Каньовська et al.
INTERNATIONAL JOURNAL OF ENDOCRINOLOGY (Ukraine)
Liver Disease Diagnosis and Treatment
article

Portal hypertension in metabolic dysfunction-associated steatotic liver disease: mechanisms of endothelial dysfunction, sinusoidal remodeling, and emerging therapeutic targets (review)

Liudmyla Mikulets, Ю. М. Яринич, А. А. Антонів, Людмила Володимирівна Каньовська, N.A. Antoniv
article en

Abstract

Background. Metabolic dysfunction-associated steatotic liver disease is one of the most prevalent chronic liver disorders worldwide and a systemic metabolic condition associated with cardiovascular, renal, and endocrine complications. Portal hypertension has traditionally been regarded as a consequence of advanced cirrhosis; however, accumulating evidence indicates that increased intrahepatic vascular resistance may develop at early stages of this disease, prior to the establishment of advanced fibrosis, warranting a comprehensive synthesis of the underlying mechanisms. The purpose of the article was to summarize and analyze current scientific evidence regarding the mechanisms underlying the development of portal hypertension in metabolic dysfunction-associated steatotic liver disease, with particular emphasis on metabolic dysregulation, endothelial dysfunction, intrahepatic microcirculatory disturbances, and fibrogenesis, and to evaluate modern diagnostic approaches and emerging therapeutic strategies targeting endothelial function and intrahepatic hemodynamics. Materials and methods. A narrative literature review was conducted using the PubMed, Scopus, Web of Science, Cochrane Library, and Google Scholar databases, covering the period from 2005 to 2025 and including systematic reviews, meta-analyses, randomized controlled and experimental studies, and clinical practice guidelines. Results. Dysfunction of liver sinusoidal endothelial cells, manifested by loss of fenestrations and sinusoidal capillarization, together with imbalance of vasoactive mediators — reduced nitric oxide bioavailability and increased endothelin-1 activity — and activation of hepatic stellate cells, constitutes a functional component of intrahepatic vascular resistance that may precede advanced fibrosis. Clinically significant portal hypertension, defined as a hepatic venous pressure gradient of 10 mmHg or more, is present in 61.5 % of patients with compensated advanced chronic liver disease related to metabolic dysfunction-associated steatotic liver disease, while the hemodynamic profile of nonalcoholic steatohepatitis differs from that of viral- or alcohol-related liver disease, particularly among patients with obesity. Conclusions. Portal hypertension in metabolic dysfunction-associated steatotic liver disease results from the interaction of functional (vascular tone) and structural (fibrosis) components of vascular resistance, accounting for the variability in clinical course. Understanding these mechanisms provides a basis for developing noninvasive diagnostic criteria and targeted therapeutic strategies aimed at restoring endothelial function at early, potentially reversible stages of the disease.

INTERNATIONAL JOURNAL OF ENDOCRINOLOGY (Ukraine)Vol. 22(7)
Bukovinian State Medical University (UA)
Liver Disease Diagnosis and Treatment
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon